Global Veterinary Medicine Market Research Report—Forecast till 2027

$4,450$6,250

Global Veterinary Medicine Market is anticipated to witness a healthy CAGR of 5.57% during the review period of 2020 to 2027. The rising rates of pet ownership, increasing chronic diseases, and growing consumption of meat are expected to create many growth opportunities for the global market.

Clear

Description

Global Veterinary Medicine Market Research Report—Forecast till 2027

Market Synopsis
Global Veterinary Medicine Market is anticipated to witness a healthy CAGR of 5.57% during the review period of 2020 to 2027. The rising rates of pet ownership, increasing chronic diseases, and growing consumption of meat are expected to create many growth opportunities for the global market. Apart from meat utilization, the dairy items request has likewise flooded. Expanding meat and dairy utilization request the security of domesticated animals and consistent checking of their wellbeing to capture the spread of illnesses from creatures to people. Amid the developing meat utilization, the emphasis on improving the wellbeing of new meat has expanded.
The global veterinary medicine market is expected to register a significant market owing to the largest value at USD 28,012.73 Million in 2019. The increasing predominance of diseases in animals poses a serious threat to food security. Climate change and globalization are the major reasons attributing to the rise in diseases among animals. Moreover, the increase in the number of pet ownerships is propelling the requirement for better care of companion animals, driving the overall expenditure on pets.
Market Segmentation
Global Veterinary Medicine Market has been classified into Animal Type, Product, Route of Administration, and Distribution Channel.
In terms of animal type, the global market has been divided into domesticated and companion.
In terms of product segments, the market is segmented into drugs and vaccines. By the route of administration, the market is categorized into oral, parental, and others. Based on the distribution channel, the market is divided into veterinary hospitals & clinics, retail stores, and online pharmacies.
Regional Analysis
Geographically, the Global Veterinary Medicine Market has been divided into the Americas, Europe, Asia-Pacific, and Middle East & Africa.
The Americas is likely to contribute the largest market owing to the increase in companion animal ownership and the rising prevalence of animal diseases in the region. As per Atlas Dental, a total of 69,075 dental operations were performed in German hospitals in 2017. Additionally, the global market growth is attributed to the increasing population of pets and livestock with a high number of veterinary practices.
Europe contributes to the second-largest market in the global veterinary medicine market during the review period. The regional market is driven by the increasing prevalence of diseases, new product approvals, and the existence of developed veterinary healthcare infrastructure.
Asia-Pacific is expected to attain the fastest-growing market during the review period. The regional market is driven by the increasing penetration of the veterinary sector, the increase in the number of private veterinary clinics, growing awareness about animal welfare, and government campaigns for the welfare of pet animals in China, Japan, India, South Korea, and Australia.
The veterinary medicine market in Middle East & Africa is anticipated to register steady growth during the forecast period owing to the presence of developing countries in the region.
Major Players
The Key Players in the Global Veterinary Medicine Market are Boehringer Ingelheim, Ceva, Chanelle Pharma Group, Dechra Pharmaceuticals plc, Elanco, Merck Animal Health, Norbrook Laboratories, Vetoquinol S.A., Bayer AG, and Zoetis.

COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

Additional information

Publisher

Geography Covered

Date Published

Pages

Format

Table of Contents

TABLE OF CONTENT
1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 SCOPE OF THE STUDY 15

2.2 RESEARCH OBJECTIVE 15

2.3 MARKET STRUCTURE 15

2.4 ASSUMPTIONS & LIMITATIONS 16

3 RESEARCH METHODOLOGY

3.1 DATA MINING 17

3.2 SECONDARY RESEARCH 18

3.3 PRIMARY RESEARCH 19

3.4 BREAKDOWN OF PRIMARY RESPONDENTS 20

3.5 FORECASTING TECHNIQUES 20

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 22

3.6.1 BOTTOM-UP APPROACH 23

3.6.2 TOP-DOWN APPROACH 23

3.7 DATA TRIANGULATION 24

3.8 VALIDATION 24

4 MARKET DYNAMICS

4.1 OVERVIEW 25

4.2 DRIVERS 26

4.2.1 GROWING RATES OF PET OWNERSHIP 26

4.2.2 RISING ZOONOTIC & CHRONIC DISEASES ANIMALS 26

4.2.3 INCREASING MEAT CONSUMPTION ATTRACTING MANDATORY VACCINATION 26

4.3 RESTRAINT 27

4.3.1 SHORTAGE OF VETERINARIANS 27

4.3.2 STRINGENT REGULATORY GUIDELINES PERTAINING TO VACCINES APPROVAL FOR ANIMALS 27

4.4 OPPORTUNITY 28

4.4.1 INCREASING INVESTMENT IN VETERINARY HOSPITALS 28

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS 29

5.1.1 R&D 30

5.1.2 MANUFACTURING 30

5.1.3 DISTRIBUTION & SALES 30

5.1.4 POST-SALES REVIEW/MONITORING 30

5.2 PORTER’S FIVE FORCES MODEL 31

5.2.1 THREAT OF NEW ENTRANTS 31

5.2.2 BARGAINING POWER OF SUPPLIERS 32

5.2.3 THREAT OF SUBSTITUTES 32

5.2.4 BARGAINING POWER OF BUYERS 32

5.2.5 INTENSITY OF RIVALRY 32

5.3 IMPACT OF COVID-19 32

5.3.1 OVERVIEW 32

5.3.2 IMPACT ON MEAT CONSUMPTION 33

5.3.3 IMPACT ON VETERINARY MEDICINE MARKET 33

6 GLOBAL VETERINARY MEDICINE MARKET, BY ANIMAL TYPE

6.1 OVERVIEW 34

6.2 DOMESTICATED 35

6.3 COMPANION 35

7 GLOBAL VETERINARY MEDICINE MARKET, BY PRODUCT

7.1 OVERVIEW 37

7.2 DRUG 38

7.3 VACCINES 39

8 GLOBAL VETERINARY MEDICINE MARKET, BY ROUTE OF ADMINISTRATION

8.1 OVERVIEW 40

8.2 ORAL 41

8.3 PARENTERAL 41

8.4 OTHERS 42

9 GLOBAL VETERINARY MEDICINE MARKET, BY DISTRIBUTION CHANNEL

9.1 OVERVIEW 43

9.2 VETERINARY HOSPITALS & CLINICS 44

9.3 RETAIL STORES 44

9.4 ONLINE PHARMACIES 45

10 GLOBAL VETERINARY MEDICINE MARKET, BY REGION

10.1 OVERVIEW 46

10.2 AMERICAS 48

10.2.1 NORTH AMERICA 50

10.2.1.1 US 52

10.2.1.2 CANADA 53

10.2.2 LATIN AMERICA 54

10.3 EUROPE 56

10.3.1 WESTERN EUROPE 58

10.3.1.1 GERMANY 60

10.3.1.2 UK 61

10.3.1.3 FRANCE 62

10.3.1.4 ITALY 63

10.3.1.5 SPAIN 64

10.3.1.6 REST OF WESTERN EUROPE 65

10.3.2 EASTERN EUROPE 67

10.4 ASIA-PACIFIC 69

10.4.1 CHINA 71

10.4.2 JAPAN 72

10.4.3 INDIA 73

10.4.4 AUSTRALIA 74

10.4.5 SOUTH KOREA 75

10.4.6 REST OF ASIA-PACIFIC 76

10.5 MIDDLE EAST & AFRICA 78

10.5.1 SAUDI ARABIA 80

10.5.2 UNITED ARAB EMIRATES 81

10.5.3 OMAN 83

10.5.4 KUWAIT 84

10.5.5 QATAR 85

10.5.6 REST OF THE MIDDLE EAST & AFRICA 86

11 COMPETITIVE LANDSCAPE

11.1 OVERVIEW 88

11.2 COMPETITIVE BENCHMARKING 89

11.3 GLOBAL VETERINARY MEDICINE MARKET: COMPANY RANKING 90

11.4 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS 91

11.5 MAJOR GROWTH STRATEGY IN THE GLOBAL VETERINARY MEDICINE MARKET 91

11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 92

11.6.1 NEW PRODUCT LAUNCHES 92

11.6.2 PARTNERSHIPS/AGREEMENTS 92

11.6.3 EXPANSIONS 93

11.6.4 ACQUISITIONS 93

11.7 FINANCIAL MATRIX 94

12 COMPANY PROFILES

12.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 96

12.1.1 COMPANY OVERVIEW 96

12.1.2 FINANCIAL OVERVIEW 97

12.1.3 PRODUCTS/SERVICES OFFERED 97

12.1.4 KEY DEVELOPMENTS 99

12.1.5 SWOT ANALYSIS 99

12.1.6 KEY STRATEGIES 100

12.2 CEVA 101

12.2.1 COMPANY OVERVIEW 101

12.2.2 FINANCIAL OVERVIEW 101

12.2.3 PRODUCTS/SERVICES OFFERED 102

12.2.4 KEY DEVELOPMENTS 102

12.2.5 SWOT ANALYSIS 103

12.2.6 KEY STRATEGIES 103

12.3 ZOETIS 104

12.3.1 COMPANY OVERVIEW 104

12.3.2 FINANCIAL OVERVIEW 104

12.3.3 PRODUCTS/SERVICES OFFERED 105

12.3.4 KEY DEVELOPMENTS 107

12.3.5 SWOT ANALYSIS 107

12.3.6 KEY STRATEGIES 107

12.4 MERCK ANIMAL HEALTH 108

12.4.1 COMPANY OVERVIEW 108

12.4.2 FINANCIAL OVERVIEW 109

12.4.3 PRODUCTS/SERVICES OFFERED 110

12.4.4 KEY DEVELOPMENTS 111

12.4.5 SWOT ANALYSIS 112

12.4.6 KEY STRATEGIES 112

12.5 CHANELLE PHARMA GROUP 113

12.5.1 COMPANY OVERVIEW 113

12.5.2 FINANCIAL OVERVIEW 113

12.5.3 PRODUCTS/SERVICES OFFERED 113

12.5.4 KEY DEVELOPMENTS 115

12.5.5 SWOT ANALYSIS 115

12.5.6 KEY STRATEGIES 115

12.6 ELANCO 116

12.6.1 COMPANY OVERVIEW 116

12.6.2 FINANCIAL OVERVIEW 117

12.6.3 PRODUCTS/SERVICES OFFERED 118

12.6.4 KEY DEVELOPMENTS 119

12.6.5 SWOT ANALYSIS 120

12.6.6 KEY STRATEGIES 120

12.7 DECHRA PHARMACEUTICALS PLC 121

12.7.1 COMPANY OVERVIEW 121

12.7.2 FINANCIAL OVERVIEW 121

12.7.3 PRODUCTS/SERVICES OFFERED 122

12.7.4 KEY DEVELOPMENTS 123

12.7.5 SWOT ANALYSIS 123

12.7.6 KEY STRATEGIES 123

12.8 BAYER AG 124

12.8.1 COMPANY OVERVIEW 124

12.8.2 FINANCIAL OVERVIEW 124

12.8.3 PRODUCTS/SERVICES OFFERED 125

12.8.4 KEY DEVELOPMENTS 126

12.8.5 SWOT ANALYSIS 127

12.8.6 KEY STRATEGIES 127

12.9 VETOQUINOL SA. 128

12.9.1 COMPANY OVERVIEW 128

12.9.2 FINANCIAL OVERVIEW 128

12.9.3 PRODUCTS/SERVICES OFFERED 129

12.9.4 KEY DEVELOPMENTS 131

12.9.5 SWOT ANALYSIS 132

12.9.6 KEY STRATEGIES 132

12.10 NORBROOK LABORATORIES 133

12.10.1 COMPANY OVERVIEW 133

12.10.2 FINANCIAL OVERVIEW 133

12.10.3 PRODUCTS/SERVICES OFFERED 133

12.10.4 KEY DEVELOPMENTS 135

12.10.5 SWOT ANALYSIS 135

12.10.6 KEY STRATEGIES 136

13 APPENDIX

13.1 REFERENCES 137

13.2 RELATED REPORTS 138

RSS
Follow by Email